Inspire - Updates in Lung Cancer

MORE videos

Latest advances in treating advanced NSCLC with driver mutations Part 1

Speaker: Keunchil Park

Latest advances in treating advanced NSCLC with driver mutations Part 2

Speaker: Keunchil Park

Latest advances in treating advanced NSCLC with driver mutations Part 3

Speaker: Keunchil Park

Latest advancement in Lung Cancer Clinical Research Part 1

Speaker: Prof. Byoung Chul Cho

Latest advancement in Lung Cancer Clinical Research Part 2

Speaker: Dr. Ross Soo

Latest advancement in Lung Cancer Clinical Research Part 3

Speakers: Prof. Byoung Chul Cho & Dr. Ross Soo

Resistance Mechanisms & Immunotherapy's Role in EGFR M+ NSLC Part 1

Speaker: Prof. Tetsuya Mitsudomi

Resistance Mechanisms & Immunotherapy's Role in EGFR M+ NSLC Part 2

Speaker: Prof. James Chih-Hsin Yang

Resistance Mechanisms & Immunotherapy's Role in EGFR M+ NSLC Part 3

Speakers: Prof. Tetsuya Mitsudomi & Prof. James Chih-Hsin Yang

Biomarker Detection in Lung Cancer : The Pros and Cons of Multiplex Testing Part 2

Speaker: Herbert Ho-Fung LOONG

Biomarker Detection in Lung Cancer : The Pros and Cons of Multiplex Testing Part 3

Speaker: Herbert Ho-Fung LOONG

The Evolving Landsacpe of Immuno-Oncology in NSCLC

Speaker: Professor James Yang

New reatment Paradigms in Early-Stage EGFR Mutant NSCLC

Speaker: Professor Yi-Long Wu

After the EGFR TKIs: Management of Advanced NSCLC Following Progression on EGFR TKIs

Speaker: Professor Tony Mok

Therapeutic Advances in Other Targetable Oncogenic Driver Mutations in NSCLC

Speaker: Professor Jin-Hyoung Kang

First Line Treatment Strategies in EGFRm NSCLC: EGFR TKIs-based Combination Treatment

Speaker: Dr Nguyen Tuan Khoi

The Year in Review : Therapeutic Advances in the Treatment of of Advanced NSCLC

Speaker: Professor Keunchil Park

New Perspectives in Diagnostic Testing in Lung Cancer

Speaker: Professor Tony Lim

First Line Treatment Strategies in EGFRm NSCLC: Osimertinib in the Upfront Approach

Speaker: Associate Professor Virute Sriuranpong

Squamous NSCLC: WHERE DO TARGETED THERAPIES FIT IN?

Speaker: Prof Shun Lu

Patient Case:AFATINIB IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE LUNG

Prof. YongFeng Yu

Closing the gap in: ADVANCED AQUAMOUS CELL LUNG CANCER MANAGEMENT(Q&A)

Dr. Ross Soo

What is Afatinib (Giotrif®)?

Afatinib (Giotrif®) is an irreversible ErbB Family blocker approved in more than 70 countries. It is indicated for the treatment of patients with distinct types of epidermal growth factor receptor mutation-positive (EGFR M+) locally advanced or metastatic non-small cell lung cancer (NSCLC), and for the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. It is an oral, once-daily, targeted therapy.[1]

*Afatinib is approved in more than 70 countries including the EU, Japan, Taiwan, and Canada under the brand name Giotrif®, in the US under the brand name Gilotrif® and in India under the brand name Xovoltib®

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about Afatinib (Giotrif®)?

The side effects of Afatinib are predictable, generally manageable and reversible. In studies to date, drug-related adverse events (AEs) were largely related to the gastrointestinal tract (diarrhoea) and skin disorders (rash), which is in line with EGFR tyrosine kinase inhibition.[1-4] For further details, please refer to the Local Prescribing Information.

References:
[1] GIOTRIF® Summary of Product Characteristics 2018
[2] Sequist L et al. J Clin Oncol 2013;31(27)3327–34.
[3] Wu YL et al. Lancet Oncol 2014;15(2):213–22.
[4] Park K et al. Lancet Oncol 2016;17(5):577–89.